NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $20.14, but opened at $21.40. NewAmsterdam Pharma shares last traded at $20.15, with a volume of 201,265 shares.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on NAMS. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a report on Monday, March 3rd. Scotiabank upped their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Needham & Company LLC lowered their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Cantor Fitzgerald began coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price on the stock. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Friday, May 30th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $42.86.
Read Our Latest Stock Report on NewAmsterdam Pharma
NewAmsterdam Pharma Stock Performance
The company's 50-day moving average is $17.78 and its 200 day moving average is $20.86. The company has a market capitalization of $2.22 billion, a PE ratio of -10.53 and a beta of -0.03.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. On average, analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.
Insider Activity
In related news, Director James N. Topper purchased 1,135 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the acquisition, the director now directly owns 3,013,569 shares in the company, valued at $67,775,166.81. This trade represents a 0.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 20.84% of the company's stock.
Institutional Trading of NewAmsterdam Pharma
Several large investors have recently bought and sold shares of NAMS. Quarry LP acquired a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at $25,000. GF Fund Management CO. LTD. acquired a new position in shares of NewAmsterdam Pharma in the 4th quarter worth $50,000. National Bank of Canada FI purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $80,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after purchasing an additional 3,390 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
